Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Treasury Shares (2020 - 2025)

Harmony Biosciences Holdings' Treasury Shares history spans 6 years, with the latest figure at $796498.0 for Q4 2025.

  • For Q4 2025, Treasury Shares rose 24.67% year-over-year to $796498.0; the TTM value through Dec 2025 reached $796498.0, up 24.67%, while the annual FY2025 figure was $796498.0, 24.67% up from the prior year.
  • Treasury Shares for Q4 2025 was $796498.0 at Harmony Biosciences Holdings, roughly flat from $799587.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $944252.0 in Q1 2025 and bottomed at $30000.0 in Q2 2023.
  • The 5-year median for Treasury Shares is $60000.0 (2021), against an average of $310719.4.
  • The largest annual shift saw Treasury Shares tumbled 50.0% in 2023 before it skyrocketed 1525.05% in 2024.
  • A 5-year view of Treasury Shares shows it stood at $60000.0 in 2021, then changed by 0.0% to $60000.0 in 2022, then surged by 450.0% to $330000.0 in 2023, then skyrocketed by 93.61% to $638900.0 in 2024, then grew by 24.67% to $796498.0 in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Treasury Shares are $796498.0 (Q4 2025), $799587.0 (Q3 2025), and $847264.0 (Q2 2025).